Eli Lilly and Company (LLY)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
At close: 04:03PM EDT
After hours:
| Previous Close | 323.35 |
| Open | 325.99 |
| Bid | 320.71 x 900 |
| Ask | 322.30 x 1100 |
| Day's Range | 317.05 - 329.35 |
| 52 Week Range | 224.22 - 341.70 |
| Volume | |
| Avg. Volume | 2,729,965 |
| Market Cap | 305.529B |
| Beta (5Y Monthly) | 0.38 |
| PE Ratio (TTM) | 51.28 |
| EPS (TTM) | 6.27 |
| Earnings Date | Nov 01, 2022 |
| Forward Dividend & Yield | 3.92 (1.21%) |
| Ex-Dividend Date | Aug 12, 2022 |
| 1y Target Est | N/A |
- Motley Fool
Is Eli Lilly Stock a Buy Following This Competitor's Major Win?
Eli Lilly (NYSE: LLY) was already having a great year in the stock market, but on Sept. 28, the company's shares jumped by about 7%. The move happened after biotech giant Biogen and its partner Esai reported positive top-line results from a phase 3 clinical trial for an Alzheimer's disease (AD) therapy candidate, lecanemab. Eli Lilly is working on its own AD treatment, donanemab, and the market counted Biogen's win as Eli Lilly's too.
- Zacks
Will Acquisitions Help Novo Nordisk (NVO) Combat Stiff Rivalry?
Novo Nordisk (NVO) expects new acquisitions to diversify its portfolio of marketed drugs and help combat the stiff competition in the diabetes market.
- Zacks
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Smart Beta ETF report for PJP
© 2022 Yahoo. All rights reserved.
